9th Annual Biomarkers Congress
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Moscone Center West
747 Howard Street San Francisco, CA 94103, United States
San Francisco, California
http://www.aacr.org/meetingcalendar
   Speakers
   --------

   N/A

   AACR
   American Association for Cancer Research

   Upcoming Conferences at the Forefront of Cancer Research

   November 12-16, 2011

   AACR - NCI - EORTC International Conference on Molecular Targets and
   Cancer Therapeutics

   Chairpersons TBD San Francisco, CA

   Please visit http://www.aacr.org/meetingcalendar often for additional
   conferences and program updates.

Schedule of Presentations:

Saturday, November 12, 2011
13:30:00 Educational Session 1 | Treatment of Premalignant Conditions Scott M Lippman
13:40:00 Preventing multiple types of cancer through HPV vaccination Douglas R LOWY
13:50:00 Use of presurgical models to screen active agents for intraepithelial neoplasia Andrea Decensi
14:00:00 Chemoprevention of lung cancer with prostacyclins or PPAR gamma agonists Paul A. Bunn
14:10:00 Cancer interception and reverse migration Scott M Lippman
15:30:00 Educational Session 2 | Clinical Trial Paradigms in the Era of Novel Therapies James H. DOROSHOW
15:40:00 New paradigms for early-phase clinical trials James H. DOROSHOW
15:50:00 Phasing out phase III trials? How much evidence do we need if the target is clearly hit? J. Verweij
16:00:00 Development of clinical trials incorporating genomic signatures: Lessons learned Lisa M McShane
16:10:00 Clinical trial designs for targeted therapies John F. Crowley
17:30:00 Networking Reception
Sunday, November 13, 2011
08:00:00 Opening Remarks and Keynote Lectures
08:10:00 Overcoming barriers to new drug development William Hait
08:20:00 Genomic profiling for personalized medicine
10:30:00 Plenary Session 1 | Novel Clinical Paradigms in Personalized Medicine José Baselga
10:40:00 Combinatorial approaches to prevent adoptive responses to targeted therapeutics in breast cancer José Baselga
10:50:00 Optimizing targeted treatment of EGFR mutant lung cancer William Pao
11:00:00 Predicting response and resistance to targeted anticancer therapeutics Levi A Garraway
11:10:00 Title to be announced
12:30:00 Poster Session A
14:30:00 Plenary Session 2 | Lessons from the BRAF-targeted Therapy of Melanoma Neal Rosen
14:40:00 Changing cell fate in cancer: Lessons from melanoma Leonard I. Zon
14:50:00 BRAF and RAS signaling in cancer | From biology to therapeutics Richard M Marais
15:00:00 BRAF and MEK inhibition in melanoma Tona M Gilmer
15:10:00 Title to be announced Neal Rosen
16:30:00 Proffered Paper Session 1
18:00:00 Poster Session A (continued)
Monday, November 14, 2011
08:00:00 Plenary Session 3 | Developing Novel Validated Preclinical Models
08:10:00 The genomics of cancer therapeutics sensitivity
08:20:00 Building more predictive in vitro and in vivo models to identify responder populations preclinically
08:30:00 Developing pancreatic cancer medicine David A Tuveson
08:50:00 Genetic and preclinical interrogation of genetically engineered mouse models of lung cancer
10:30:00 Plenary Session 4 | Mechanistic-based Immunotherapy Cornelis J.M. Melief
10:40:00 Sipuleucel-T and the active immunotherapy of prostate cancer David Urdal
10:50:00 Development of ipilimumab (anti-CTLA-4) and beyond: Contribution to a new immunotherapy paradigm Axel Hoos
11:00:00 Engineering improved cancer vaccines Glenn Dranoff
11:10:00 Synthetic long peptide vaccines against established disease caused by high-risk human papillomavirus Cornelis J.M. Melief
12:30:00 Poster Session B
14:25:00 Concurrent Sessions 1-4
14:30:00 Concurrent Session 4 | Pharmacogenomics and Pharmacogenetics
14:30:00 Concurrent Session 3 | Challenges in PI3K Inhibition Jean- -Charles Soria
14:30:00 Concurrent Session 1 | Finding the Best New Cancer Targets Paul Workman
14:30:00 Concurrent Session 2 | Mechanism-based Targeted Combination Therapies William C Hahn
14:40:00 Concurrent Session 2 | Functional genomics to identify targets and resistance William C Hahn
14:40:00 Concurrent Session 4 | Polymorphic transporters and oncology drug safety Alex Sparreboom
14:40:00 Concurrent Session 3 | Mechanistic basis for treatment combinations with PI3K inhibitors Carlos L. Arteaga
14:40:00 Concurrent Session 1 | Finding the best new cancer targets: Approaches and challenges Paul Workman
14:50:00 Concurrent Session 1 | canSAR: An integrated cancer drug discovery informatics platform allowing systematic target evaluation
14:50:00 Concurrent Session 4 | Interrogating the heritable genome to achieve the goal of personalized cancer therapeutics Federico Innocenti
14:50:00 Concurrent Session 3 | Clinical development strategies of PI3K inhibitors Mika Derynck
14:50:00 Concurrent Session 2 | Dual inhibition of mTOR and IGFR pathways
15:00:00 Concurrent Session 3 | Title to be announced Patricia LoRusso
15:00:00 Concurrent Session 1 | Identification of high-value targets for oncology drug discovery: Cancer genetics, synthetic lethality, and beyond
15:00:00 Concurrent Session 2 | Targeting epigenomic and apoptotic proteins and pathways to treat leukemia and lymphoma
15:00:00 Concurrent Session 4 | Somatic driver mutations as a guide for anticancer treatment in lung cancer Bruce E. Johnson
15:10:00 Concurrent Session 3 | PI3K pathway inhibitors: How deep should we go? Josep Tabernero
15:10:00 Concurrent Session 2 | Mechanisms of resistance to receptor tyrosine kinase inhibitors revealed through functional genetic screens René Bernards
15:10:00 Concurrent Session 1 | Identifying druggable targets from alterations in the cancer genome Matthew Meyerson
15:10:00 Concurrent Session 4 | Pharmacogenetic findings translated into clinical predictive biomarkers
16:30:00 Proffered Paper Session 2
18:00:00 Poster Session B (continued)
Tuesday, November 15, 2011
08:00:00 Plenary Session 5 | The Epigenome as a Therapeutic Target
08:10:00 MMSET | A pathogenic factor and therapeutic target in multiple myeloma Jonathan D Licht
08:20:00 Novel agents for epigenetic therapy Jean-Pierre Issa
08:30:00 Molecular basis and novel options for alternative epigenetic treatments against cancer
09:10:00 Targeting histone methyltransferases in tumor-sustaining cells Robert Brown
10:30:00 Plenary Session 6 | Targeting Tumor Stroma Interaction Nadia Harbeck
10:40:00 Impact of breast tumor microenvironment on treatment efficacy FABRICE ANDRE
10:50:00 Premetastatic niche | Opportunity for early intervention? David C Lyden
11:00:00 Urokinase plasminogen activator system | A multifunctional drug target Nadia Harbeck
11:10:00 Targeting the tumor ecosystem | Translating the molecular biology of chemokine interactions to the clinic Kenneth J Pienta
12:30:00 Poster Session C
14:25:00 Concurrent Sessions 5-8
14:30:00 Concurrent Session 5 | Targeting DNA Damage Response Beverly A Teicher
14:30:00 Concurrent Session 7 | Challenges in Genomic-based Characterization of Tumors Lynda Chin
14:30:00 Concurrent Session 8 | Advances in Targeted Hormonal Therapies Johann S. de Bono
14:30:00 Concurrent Session 6 | Inhibition of Stem Cell Signaling Daniel Von Hoff
14:40:00 Concurrent Session 5 | Mdm2 regulates DNA repair and chromosome stability
14:40:00 Concurrent Session 7 | Accessing and using data from the International Cancer Genome Consortium (ICGC) to get insights into cancer genomes
14:40:00 Concurrent Session 6 | Low dose azacytidine and epigenetic regulation of self renewal
14:40:00 Concurrent Session 8 | Targeting the androgen receptor in castration-resistant prostate cancer Donald J Tindall
14:50:00 Concurrent Session 7 | Target discovery with Oncomine: Discovering new targets and positioning old targets by integrative analysis of 10,000’s of tumor genomes and transcriptomes Daniel R. Rhodes
14:50:00 Concurrent Session 5 | Targeting the Fanconi anemia/BRCA pathway in cancer therapy
14:50:00 Concurrent Session 6 | The cancer stem cell niche Joan Seoane
14:50:00 Concurrent Session 8 | Androgens, biomarkers, and abiraterone Johann S. de Bono
15:00:00 Concurrent Session 8 | Neoadjuvant androgen deprivation therapy for high-risk prostate cancer
15:00:00 Concurrent Session 6 | Regulation of breast cancer stem cells by cytokine networks Max S Wicha
15:00:00 Concurrent Session 5 | Targeting molecular chaperones to induce telomere dysfunction
15:00:00 Concurrent Session 7 | Title to be announced Lynda Chin
15:10:00 Concurrent Session 5 | Opportunities for targeting homologous recombination in human cancers
15:10:00 Concurrent Session 7 | Title to be announced
15:10:00 Concurrent Session 6 | The hedgehog signaling pathway in cancer William H. Matsui
15:10:00 Concurrent Session 8 | A combinatorial approach to targeting androgen receptor signaling in prostate cancer Wayne Tilley
16:30:00 Poster Session C (continued)
Wednesday, November 16, 2011
08:00:00 Plenary Session 7 | Rational Cancer Drug Development for Targeted Drugs: The Interface Between Industry, Academia, and Regulators Frank McCormick
08:10:00 Title to be announced
08:20:00 Title to be announced Richard B Gaynor
08:30:00 FDA role in smoothing the progress of targeted drug development A. J. Murgo
09:00:00 Panelists
10:30:00 Plenary Session 8 | Targeting Tumor Metabolism
10:40:00 Clinical achievements reached by interfering with the IGF1R–PI3K–PTEN–AKT–mTOR axis
10:50:00 HIF-1 and reprogramming of cancer cell metabolism: Opportunities for therapy
11:00:00 Is there a role for metformin in cancer therapeutics? Ana Gonzalez-Angulo
11:10:00 New ways to impact glutamine metabolism in cancer
12:30:00 Closing Remarks | Adjournment
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.